389 related articles for article (PubMed ID: 23249810)
1. Twice-daily application of HIV microbicides alter the vaginal microbiota.
Ravel J; Gajer P; Fu L; Mauck CK; Koenig SS; Sakamoto J; Motsinger-Reif AA; Doncel GF; Zeichner SL
mBio; 2012 Dec; 3(6):. PubMed ID: 23249810
[TBL] [Abstract][Full Text] [Related]
2. Clinical development of microbicides for the prevention of HIV infection.
D'Cruz OJ; Uckun FM
Curr Pharm Des; 2004; 10(3):315-36. PubMed ID: 14754390
[TBL] [Abstract][Full Text] [Related]
3. Toward early safety alert endpoints: exploring biomarkers suggestive of microbicide failure.
Mauck CK; Lai JJ; Weiner DH; Chandra N; Fichorova RN; Dezzutti CS; Hillier SL; Archer DF; Creinin MD; Schwartz JL; Callahan MM; Doncel GF
AIDS Res Hum Retroviruses; 2013 Nov; 29(11):1475-86. PubMed ID: 23885658
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the vaginal microbial communities in women with recurrent genital HSV receiving acyclovir intravaginal rings.
Ursell LK; Gunawardana M; Chang S; Mullen M; Moss JA; Herold BC; Keller MJ; McDonald D; González A; Knight R; Baum MM
Antiviral Res; 2014 Feb; 102():87-94. PubMed ID: 24361269
[TBL] [Abstract][Full Text] [Related]
5. Novel vaginal microflora colonization model providing new insight into microbicide mechanism of action.
Fichorova RN; Yamamoto HS; Delaney ML; Onderdonk AB; Doncel GF
mBio; 2011; 2(6):e00168-11. PubMed ID: 22027006
[TBL] [Abstract][Full Text] [Related]
6. Deep sequencing of the vaginal microbiota of women with HIV.
Hummelen R; Fernandes AD; Macklaim JM; Dickson RJ; Changalucha J; Gloor GB; Reid G
PLoS One; 2010 Aug; 5(8):e12078. PubMed ID: 20711427
[TBL] [Abstract][Full Text] [Related]
7. Vaginal microbiota of adolescent girls prior to the onset of menarche resemble those of reproductive-age women.
Hickey RJ; Zhou X; Settles ML; Erb J; Malone K; Hansmann MA; Shew ML; Van Der Pol B; Fortenberry JD; Forney LJ
mBio; 2015 Mar; 6(2):. PubMed ID: 25805726
[TBL] [Abstract][Full Text] [Related]
8. Vaginal microbicides for reducing the risk of sexual acquisition of HIV infection in women: systematic review and meta-analysis.
Obiero J; Mwethera PG; Hussey GD; Wiysonge CS
BMC Infect Dis; 2012 Nov; 12():289. PubMed ID: 23130761
[TBL] [Abstract][Full Text] [Related]
9. Associations of the vaginal microbiota with HIV infection, bacterial vaginosis, and demographic factors.
Chehoud C; Stieh DJ; Bailey AG; Laughlin AL; Allen SA; McCotter KL; Sherrill-Mix SA; Hope TJ; Bushman FD
AIDS; 2017 Apr; 31(7):895-904. PubMed ID: 28121709
[TBL] [Abstract][Full Text] [Related]
10. Appropriateness of hydroxyethylcellulose gel as a placebo control in vaginal microbicide trials: a comparison of the two control arms of HPTN 035.
Richardson BA; Kelly C; Ramjee G; Fleming T; Makanani B; Roberts S; Musara P; Mkandawire N; Moench T; Coletti A; Soto-Torres L; Karim SA;
J Acquir Immune Defic Syndr; 2013 May; 63(1):120-5. PubMed ID: 23334506
[TBL] [Abstract][Full Text] [Related]
11. Topical microbicides for prevention of sexually transmitted infections.
Obiero J; Mwethera PG; Wiysonge CS
Cochrane Database Syst Rev; 2012 Jun; (6):CD007961. PubMed ID: 22696373
[TBL] [Abstract][Full Text] [Related]
12. Association between cigarette smoking and the vaginal microbiota: a pilot study.
Brotman RM; He X; Gajer P; Fadrosh D; Sharma E; Mongodin EF; Ravel J; Glover ED; Rath JM
BMC Infect Dis; 2014 Aug; 14():471. PubMed ID: 25169082
[TBL] [Abstract][Full Text] [Related]
13. Unique vaginal microbiota that includes an unknown Mycoplasma-like organism is associated with Trichomonas vaginalis infection.
Martin DH; Zozaya M; Lillis RA; Myers L; Nsuami MJ; Ferris MJ
J Infect Dis; 2013 Jun; 207(12):1922-31. PubMed ID: 23482642
[TBL] [Abstract][Full Text] [Related]
14. Heterosexual anal intercourse has the potential to cause a significant loss of power in vaginal microbicide effectiveness studies.
McGowan I; Taylor DJ
Sex Transm Dis; 2010 Jun; 37(6):361-4. PubMed ID: 20514687
[TBL] [Abstract][Full Text] [Related]
15. Historical development of vaginal microbicides to prevent sexual transmission of HIV in women: from past failures to future hopes.
Notario-Pérez F; Ruiz-Caro R; Veiga-Ochoa MD
Drug Des Devel Ther; 2017; 11():1767-1787. PubMed ID: 28670111
[TBL] [Abstract][Full Text] [Related]
16. Optimizing HIV prevention for women: a review of evidence from microbicide studies and considerations for gender-sensitive microbicide introduction.
Doggett EG; Lanham M; Wilcher R; Gafos M; Karim QA; Heise L
J Int AIDS Soc; 2015; 18(1):20536. PubMed ID: 26700845
[TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo characterization of a potential universal placebo designed for use in vaginal microbicide clinical trials.
Tien D; Schnaare RL; Kang F; Cohl G; McCormick TJ; Moench TR; Doncel G; Watson K; Buckheit RW; Lewis MG; Schwartz J; Douville K; Romano JW
AIDS Res Hum Retroviruses; 2005 Oct; 21(10):845-53. PubMed ID: 16225411
[TBL] [Abstract][Full Text] [Related]
18. Phase 1 randomized trial of the vaginal safety and acceptability of SPL7013 gel (VivaGel) in sexually active young women (MTN-004).
McGowan I; Gomez K; Bruder K; Febo I; Chen BA; Richardson BA; Husnik M; Livant E; Price C; Jacobson C;
AIDS; 2011 May; 25(8):1057-64. PubMed ID: 21505316
[TBL] [Abstract][Full Text] [Related]
19. Safety study of nonoxynol-9 as a vaginal microbicide: evidence of adverse effects.
Stafford MK; Ward H; Flanagan A; Rosenstein IJ; Taylor-Robinson D; Smith JR; Weber J; Kitchen VS
J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Apr; 17(4):327-31. PubMed ID: 9525433
[TBL] [Abstract][Full Text] [Related]
20. Phase I randomized safety study of twice daily dosing of acidform vaginal gel: candidate antimicrobial contraceptive.
Keller MJ; Carpenter CA; Lo Y; Einstein MH; Liu C; Fredricks DN; Herold BC
PLoS One; 2012; 7(10):e46901. PubMed ID: 23056520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
